References

mrj

Современная ревматология

Modern Rheumatology Journal

1996-70122310-158X

IMA-PRESS, LLC

10.14412/1996-7012-2021-6-7-12

mrj-1220

Research Article

ЛЕКЦИИ

LECTURES

Актуальные вопросы ведения пациентов с ВИЧ-инфекцией и ревматическими заболеваниями

Current issues in the management of patients with HIV infection and rheumatic diseases

https://orcid.org/0000-0002-0928-3911

Гриднева

Г. И.

Gridneva

G. I.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe shosse, Moscow 115522

gigridneva@mail.ru

https://orcid.org/0000-0001-7091-2054

Белов

Б. С.

Belov

B. S.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe shosse, Moscow 115522

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation

2021

13122021

156712

2021

Гриднева Г.И., Белов Б.С.

Gridneva G.I., Belov B.S.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://mrj.ima-press.net/mrj/article/view/1220

По оценкам экспертов, эпидемия вируса иммунодефицита человека (ВИЧ) имеет устойчивую тенденцию к спаду, однако внимание медицинского сообщества к данной проблеме не ослабевает. До внедрения высокоактивной антиретровирусной терапии распространенность ревматических проявлений у ВИЧ-инфицированных больных составляла от 3 до 71% и была связана с поздними стадиями инфекции и выраженной иммуносупрессией. ВИЧ-ассоциированный артрит, реактивный артрит, псориатический артрит, артралгии и синдром диффузного инфильтративного лимфоцитоза – наиболее частая ревматическая патология при ВИЧ. Большинство лиц, страдающих ВИЧ и воспалительным поражением опорно-двигательного аппарата, хорошо отвечают на нестероидные противовоспалительные препараты, опиоиды и базисные противовоспалительные препараты. В случаях, торпидных к указанному лечению, может потребоваться применение генно-инженерных биологических препаратов. В лекции обобщены современные данные, касающиеся особенностей течения и лечения иммуновоспалительных ревматических заболеваний при ВИЧ-инфекции.

According to experts, the human immunodeficiency virus (HIV) epidemic has a steady downward trend, but the attention of the medical community to this problem is not waning. Before the introduction of highly active antiretroviral therapy, the prevalence of rheumatic manifestations in HIV-infected patients ranged from 3 to 71% and was associated with late stages of infection and severe immunosuppression. HIV-associated arthritis, reactive arthritis, psoriatic arthritis, arthralgias and diffuse infiltrative lymphocytosis syndrome are the most common rheumatic pathologies in HIV. Most people with HIV and musculoskeletal inflammatory disease respond well to NSAIDs, opioids, and basic anti-inflammatory drugs. In cases that are torpid to the abovementioned treatment, the use of biologic disease-modifying antirheumatic drugs may be required.

The lecture summarizes modern data on the features of the course and treatment of immunoinflammatory rheumatic diseases in HIV infection.

ВИЧ-инфекциягенно-инженерные биологические препаратыбазисные противовоспалительные препаратывысокоактивная антиретровирусная терапия

HIV infectionbiologic disease-modifying antirheumatic drugsdisease-modifying antirheumatic drugshighly active antiretroviral therapy

References1

ВИЧ-инфекция у взрослых. Клинические рекомендации. 2019. http://rushiv.ru/wp-content/uploads/2019/12/KP79-19-2.pdf

HIV infection in adults. Clinical recommendations. 2019. http://rushiv.ru/wp-content/uploads/2019/12/KP79-19-2.pdf

Справка. ВИЧ-инфекция в Российской Федерации на 30 июня 2021 г. http://www.hivrussia.info/

Reference. HIV infection in the Russian Federation as of June 30, 2021. http://www.hivrussia.info/

Fox C, Walke-Bone K. Evolving spectrum of HIV-associated rheumatic syndromes. Best Pract Res Clin Rheumatol. 2015 Apr;29(2): 244-58. doi: 10.1016/j.berh.2015.04.019. Epub 2015 May 23.

Малышенко ОС, Раскина ТА, Аверкиева ЮВ и др. Суставной синдром у ВИЧ-инфицированного пациента. Современная ревматология. 2020;14(4):161-64. doi: 10.14412/1996-7012-2020-4-161-164

Malyshenko OS, Raskina TA, Averkieva Yu V, et al. Articular syndrome in an HIV-infected patient. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2020;14(4): 161-64. (In Russ.). doi: 10.14412/1996-7012-2020-4-161-164

Пономарева ЕЮ, Шульдяков АА, Анащенко АВ, Ребров АП. Клиническая манифестация ВИЧ-инфекции, имитирующая ревматические заболевания. Научно-практическая ревматология. 2018; 56(4):525-30.

Ponomareva EYu, Shuldyakov AA, Anashchenko AV, Rebrov AP. The clinical manifestation of HIVinfection simulating rheumatic diseases. Nauchno-Prakticheskaya Revmatologiya. 2018;56(4):525-30 (In Russ.).

Reveille JD, Williams FM. Infection and musculoskeletal conditions: Rheumatologic complications of HIV infection. Best Pract Res Clin Rheumatol. 2006 Dec;20(6):1159-79. doi: 10.1016/j.berh.2006.08.015.

Буханова ДВ, Белов БС. Поражение суставов при ВИЧ-инфекции. Медицинский cовет. 2018;(9):82-7.

Bukhanova DV, Belov BS. Joint damage in HIV positive patients. Meditsinskii sovet. 2018;(9):82-7. (In Russ.).

Mallon E, Bunker CB. HIV-associated psoriasis. AIDS Patient Care STDS. 2000 May; 14(5):239-46. doi: 10.1089/108729100317696.

Chitra P, Bakthavatsalam B, Palvannan T. Osteonecrosis with renal damage in HIV patients undergoing HAART. Biomed Pharmacother. 2014 Sep;68(7):881-5. doi: 10.1016/j.biopha.2014.07.017. Epub 2014 Aug 1.

Nicholson P, Saunsbury E, D'Angelo S, et al. Prevalence of and risk factors for gout in HIV-positive adults: A case-control study. Int J STD AIDS. 2019 Mar;30(3):249-55. doi: 10.1177/0956462418799803. Epub 2018 Nov 4.

Saigal R, Chakraborty A, Yadav RN, Goyal LK. Rheumatological Manifestations in HIV-Positive Patients: A Single-Center Study. Adv Ther. 2020 Oct;37(10):4336-45. doi: 10.1007/s12325-020-01470-3. Epub 2020 Aug 24.

WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children (PDF). Geneva: World Health Organization; 2007. P. 6-16.

Hanberg JS, Hsieh E, Akgü n KM, et al. Incident Rheumatoid Arthritis in Human Immunodeficiency Virus Infection: Epidemiology and Treatment. Arthritis Rheumatol. 2021 May 27. doi: 10.1002/art.41802. Online ahead of print.

Dotan I, Riesenberg K, Toledano R, et al. Prevalence and characteristics of fibromyalgia among HIV-positive patients in southern Israel. Clin Exp Rheumatol. Mar-Apr 2016;34 (2 Suppl 96):S34-9. Epub 2016 Mar 3.

Liu Y, Foreman SC, Joseph GB, et al. Is treated HIV infection associated with knee cartilage degeneration and structural changes? A longitudinal study using data from the osteoarthritis initiative. BMC Musculoskelet Disord. 2019 May 4;20(1):190. doi: 10.1186/s12891-019-2573-5.

Tomi AL, Sellam J, Lacombe K, et al. Increased prevalence and severity of radiographic hand osteoarthritis in patients with HIV-1 infection associated with metabolic syndrome: data from the cross-sectional METAFIB-OA study. Ann Rheum Dis. 2016 Dec;75(12):2101-7. doi: 10.1136/annrheumdis-2016-209262. Epub 2016 Mar 31.

Gallitano S, McDermott L, Brar K, Lowenstein E. Use of tumor necrosis factor (TNF) inhibitors in patients with HIV/AIDS. J Am Acad Dermatol. 2016 May;74(5):974-80. doi: 10.1016/j.jaad.2015.11.043. Epub 2016 Jan 14.

Adizie T, Moots RJ, Hodkinson B, et al. Inflammatory arthritis in HIV positive patients: a practical guide. BMC Infect Dis. 2016 Mar 1;16:100. doi: 10.1186/s12879-016-1389-2.

Packham J, Arkell P, Sheeran T, et al. Patient experiences, attitudes and expectations towards receiving information about anti-TNF medication: a quantitative study. Clin Rheumatol. 2017 Nov;36(11):2595-600. doi: 10.1007/s10067-017-3642-5. Epub 2017 May 19.

Fink DL, Hedley L, Miller RF. Systematic review of the efficacy and safety of biological therapy for inflammatory conditions in HIVinfected individuals. Int J STD AIDS. 2017 Feb; 28(2):110-9. doi: 10.1177/0956462416675109. Epub 2016 Oct 13.

O'Kelly B, McNally C, McConkey S, Durcan L. HIV and systemic lupus erythematosus: where immunodeficiency meets autoimmunity. Lupus. 2020 Aug;29(9): 1130-2. doi: 10.1177/0961203320934851. Epub 2020 Jun 22.

Vega LE, Espinoza LR. Human immunodeficiency virus infection (HIV)-associated rheumatic manifestations in thepre- and post-HAART eras. Clin Rheumatol. 2020 Sep; 39(9):2515-22. doi: 10.1007/s10067-020- 05082-8. Epub 2020 Apr 15. 23. Cepeda EJ, Williams FM, Ishimori ML, et al. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis. 2008 May; 67(5):710-2. doi: 10.1136/ard.2007.081513. Epub 2007 Dec 13.

Wangsiricharoen S, Ligon C, Gedmintas L, et al. Rates of Serious Infections in HIVInfected Patients Receiving Tumor Necrosis Factor Inhibitor Therapy for Concomitant Autoimmune Diseases. Arthritis Care Res (Hoboken). 2017 Mar;69(3):449-52. doi: 10.1002/acr.22955.

Curtis JR, Jain A, Askling J, et al. A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum. 2010 Aug;40(1):2-14.e1. doi: 10.1016/j.semarthrit.2010.03.003.

Narcisi A, Bernardini N, Orsini D, et al. Long-term safety and efficacy of adalimumab in psoriasis: a multicentric study focused on infections (connecting study). Postepy Dermatol Alergol. 2020 Jun;37(3):428-34. doi: 10.5114/ada.2020.96910. Epub 2020 Jul 16.

Liang SJ, Zheng QY, Yang YL, et al. Use of etanercept to treat rheumatoid arthritis in an HIV-positive patient: a case-based review. Rheumatol Int. 2017 Jul;37(7):1207-12. doi: 10.1007/s00296-017-3690-9. Epub 2017 Mar 2.

Mariappan AL, Desai S, Locante A, et al. Iatrogenic Kaposi Sarcoma Precipitated by Anti-Tumor Necrosis Factor-Alpha (Anti-TNF-α) Therapy. Cureus. 2021 Feb 16; 13(2):e13384. doi: 10.7759/cureus.13384.

Paparizos V, Rallis E, Kirsten L, Kyriakis K. Ustekinumab for the treatment of HIV psoriasis. J Dermatolog Treat. 2012 Dec;23(6): 398-9. doi: 10.3109/09546634.2011.579085. Epub 2011 Jul 25.

Saeki H, Ito T, Hayashi M, et al. Successful treatment of ustekinumab in a severe psoriasis patient with human immunodeficiency virus infection. J Eur Acad Dermatol Venereol. 2015 Aug;29(8):1653-5. doi: 10.1111/jdv.12531. Epub 2014 Apr 23.

Bardazzi F, Magnano M, Campanati A, et al. Biologic Therapies in HIV-infected Patients with Psoriasis: An Italian Experience. Acta Derm Venereol. 2017 Aug 31;97(8): 989-90. doi: 10.2340/00015555-2698.

Wang DM, Fernandez AP, Calabrese CM, Calabrese LH. Treatment of psoriasis with ustekinumab in a patient with HIV-related Kaposi sarcoma. Clin Exp Dermatol. 2019 Jan; 44(1):113-5. doi: 10.1111/ced.13630. Epub 2018 May 24.

Marcelin AG, Aaron L, Mateus C, et al. Rituximab therapy for HIV-associated Castleman disease. Blood. 2003 Oct 15;102(8): 2786-8. doi: 10.1182/blood-2003-03-0951. Epub 2003 Jul 3.

Habbous S, Guo H, Beca J, et al. The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B-cell lymphoma. Cancer Med. 2020 Oct;9(19):7072-82. doi: 10.1002/cam4.3362. Epub 2020 Aug 13.

Zalmanovich A, Ben-Ami R, Rahav G, et al. Rituximab identified as an independent risk factor for severe PJP: A case-control study. PLoS One. 2020 Sep 11;15(9): e0239042. doi: 10.1371/journal.pone.0239042. eCollection 2020.

Gavegnano C, Detorio M, Montero C et al. Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro. Antimicrob Agents Chemother. 2014;58(4):1977-86. doi: 10.1128/AAC.02496-13. Epub 2014 Jan 13.

Hoff P, Walther M, Wesselmann H, et al. Erfolgreiche Behandlung eines adulten Morbus Still mit Tofacitinib bei einer HIV-2- positiven Patientin. Z Rheumatol. 2020 Dec; 79(10):1046-9. doi: 10.1007/s00393-020-00853-9.

Bottlaender L, Seve P, Cotte L, et al. Successful treatment with anakinra of an HIV-associated immune reconstitution inflammatory syndrome mimicking adultonset Still's disease. Rheumatology (Oxford). 2019 Feb 1;58(2):363-5. doi: 10.1093/rheumatology/key291.

The authors declare that there are no conflicts of interest present.